Expanded Access Program With Nivolumab to Treat Melanoma
NCT ID: NCT02142218
Last Updated: 2016-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NO_LONGER_AVAILABLE
EXPANDED_ACCESS
2014-06-30
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
NCT02156804
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
NCT02186249
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
NCT02599402
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
NCT03635983
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
NCT02388906
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nivolumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed malignant melanoma
* Progressed on or after treatment with an anti-CTLA4
Exclusion Criteria
* Life Expectancy \<6 weeks
* Subjects who received prior therapy targeting T-cell costimulation or checkpoint pathways except for Anti CTLA-4 therapy
* Subjects with autoimmune disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Mobile, Alabama, United States
Southern Cancer Center Pc
Mobile, Alabama, United States
Local Institution
Encinitas, California, United States
Local Institution
Washington D.C., District of Columbia, United States
Lynn Cancer Institute At Boca Raton Regional Hospital
Boca Raton, Florida, United States
Cancer Specialists Of North Florida
Jacksonville, Florida, United States
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
Florida Hospital
Orlando, Florida, United States
Winship Cancer Institute
Atlanta, Georgia, United States
Summit Cancer Care
Savannah, Georgia, United States
Oncology Specialists, S.C.
Park Ridge, Illinois, United States
Oncology Hematology Associates Of Sw In
Newburgh, Indiana, United States
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Lutherville, Maryland, United States
Nebraska Cancer Specialists
Omaha, Nebraska, United States
Comprehensive Cancer Centers Of Nevada
Las Vegas, Nevada, United States
North Shore Hematology/Oncology Associates, P.C.
East Setauket, New York, United States
Icahn School Of Medicine At Mount Sinai
New York, New York, United States
Mid Ohio Oncology/Hematology, Inc,Dba
Columbus, Ohio, United States
Lehigh Valley Health Network
Allentown, Pennsylvania, United States
St. Luke'S Hospital
Bethlehem, Pennsylvania, United States
The Jones Clinic, Pc
Germantown, Tennessee, United States
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Waukesha Memorial Hospital
Waukesha, Wisconsin, United States
Local Institution
Buenos Aires, Buenos Aires, Argentina
Local Institution
Buenos Aires, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Local Institution
Córdoba, Córdoba Province, Argentina
Local Institution
Rosario, Santa Fe Province, Argentina
Local Institution
San Miguel de Tucumán, Tucumán Province, Argentina
Local Institution
San Miguel de Tucumán, Tucumán Province, Argentina
Local Institution
Caba, , Argentina
Local Institution
Fortaleza, Ceará, Brazil
Local Institution
Salvador, Estado de Bahia, Brazil
Local Institution
Brasília, Federal District, Brazil
Local Institution
Belo Horizonte, Minas Gerais, Brazil
Local Institution
Belo Horizonte, Minas Gerais, Brazil
Local Institution
Jd. Petropolis-Londrina, Paraná, Brazil
Local Institution
Ijuí, Rio Grande do Sul, Brazil
Local Institution
Passo Fundo, Rio Grande do Sul, Brazil
Local Institution
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution
Florianópolis, Santa Catarina, Brazil
Local Institution
Itajaí, Santa Catarina, Brazil
Local Institution
Barretos, São Paulo, Brazil
Local Institution
Jaú, São Paulo, Brazil
Local Institution
Ribeirão Preto, São Paulo, Brazil
Local Institution
Santo André, São Paulo, Brazil
Local Institution
São José do Rio Preto, São Paulo, Brazil
Local Institution
São Paulo, São Paulo, Brazil
Local Institution
São Paulo, São Paulo, Brazil
Local Institution
São Paulo, São Paulo, Brazil
Local Institution
São Paulo, São Paulo, Brazil
Local Institution
São Paulo, São Paulo, Brazil
Local Institution
São Paulo, São Paulo, Brazil
Local Institution
Calgary, Alberta, Canada
Local Institution
Edmonton, Alberta, Canada
Local Institution
Kelowna, British Columbia, Canada
Local Institution
North Vancouver, British Columbia, Canada
Local Institution
Vancouver, British Columbia, Canada
Local Institution
Winnipeg, Manitoba, Canada
Local Institution
Moncton, New Brunswick, Canada
Local Institution
St. John's, Newfoundland and Labrador, Canada
Local Institution
Halifax, Nova Scotia, Canada
Local Institution
Hamilton, Ontario, Canada
Local Institution
London, Ontario, Canada
Local Institution
Ottawa, Ontario, Canada
Local Institution
Toronto, Ontario, Canada
Local Institution
Toronto, Ontario, Canada
Local Institution
Montreal, Quebec, Canada
Local Institution
Québec, Quebec, Canada
Local Institution
Saskatoon, Saskatchewan, Canada
Local Institution
Bogotá, , Colombia
Local Institution
Bogotá, , Colombia
Local Institution
Cali, , Colombia
Local Institution
Medellín, , Colombia
Local Institution
Medellín, , Colombia
Local Institution
Lima, Lima Province, Peru
Local Institution
Lima, Lima Province, Peru
Local Institution
Lima, , Peru
Local Institution
Lima, , Peru
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS clinical trial educational resource
Investigator Inquiry form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA209-168
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.